Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439236 | 0.92 | GAA (0.52) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL27242011 | 0.80 | GAA (0.55) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL8942203 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL24378546 | 0.79 | DPP4 (0.45) | DPP4DPP8DPP9GAAKDM4E | |
| SCHEMBL3038457 | 0.78 | GAA (0.56) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL13242132 | 0.78 | GAA (0.56) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL18990731 | 0.77 | GAA (0.54) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL8350773 | 0.76 | DPP4 (0.41) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL21379846 | 0.76 | GAA (0.53) | DPP4DPP8DPP9GAAGABRA2 | |
| SCHEMBL1283036 | 0.76 | GAA (0.53) | DPP4DPP8DPP9GAAGABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | DPP4 1014/4885DPP8 1362/4885DPP9 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.